Eurobio Scientific Société anonyme (EPA:ALERS)

Market Cap	201.37M -21.0%
Revenue (ttm)	168.60M +9.1%
Net Income	4.87M +21.7%
EPS	0.47 +20.5%
Shares Out	10.07M
PE Ratio	42.55
Forward PE	17.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	811
Open	20.50
Previous Close	20.00
Day's Range	20.20 - 21.20
52-Week Range	19.30 - 25.70
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 24, 2026

About EPA:ALERS

Eurobio Scientific Société anonyme engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences. The company produces and markets transport and preservation media for corneal grafts; AlloMap, for heart transplant follow up; cell culture media, molecular biology reagents, contract manufacturing service, and proprietary antibodies; TQS (Tetanus Quick Stick), a rapid test used in emergency departments or pharmacies to assess the vaccina...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 343
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALERS

Financial Performance

In 2025, EPA:ALERS's revenue was 168.60 million, an increase of 9.08% compared to the previous year's 154.56 million. Earnings were 4.87 million, an increase of 21.69%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 3, 2026

Data Sources Report a data error